Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
ITERUM THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
Do | Iterum Therapeutics plc - 8-K, Current Report | 1 | SEC Filings | ||
20.08. | Iterum brings first oral penem antibiotic to US market | - | pharmaphorum | ||
20.08. | Iterum Therapeutics startet US-Markteinführung für neues Antibiotikum gegen Harnwegsinfekte | 1 | Investing.com Deutsch | ||
20.08. | Iterum launches first oral penem antibiotic for urinary tract infections | 2 | Investing.com | ||
20.08. | Iterum Therapeutics plc - 8-K, Current Report | 4 | SEC Filings | ||
20.08. | Iterum Therapeutics PLC: Iterum Therapeutics launches ORLYNVAH, the first and only oral penem antibiotic in the U.S. | 149 | GlobeNewswire (Europe) | DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by... ► Artikel lesen | |
05.08. | Iterum Therapeutics plc - 10-Q, Quarterly Report | 4 | SEC Filings | ||
05.08. | Iterum Therapeutics PLC: Iterum Therapeutics Reports Second Quarter 2025 Financial Results | 116 | GlobeNewswire (Europe) | -- Launch of ORLYNVAHTM Expected August 2025- --Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics... ► Artikel lesen | |
04.08. | Insights Ahead: Iterum Therapeutics' Quarterly Earnings | 2 | Benzinga.com | ||
04.08. | Iterum Therapeutics plc - 8-K, Current Report | 1 | SEC Filings | ||
29.07. | Iterum Therapeutics PLC: Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 | 2 | GlobeNewswire (USA) | ||
18.07. | Iterum Therapeutics plc - 8-K, Current Report | 1 | SEC Filings | ||
02.07. | Iterum Therapeutics PLC: Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 119 | GlobeNewswire (Europe) | DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics... ► Artikel lesen | |
30.06. | Iterum Therapeutics PLC: Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH Launch and Commercial Growth | 183 | GlobeNewswire (Europe) | DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics... ► Artikel lesen | |
25.06. | Iterum Therapeutics PLC: Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence | 1 | GlobeNewswire (USA) | ||
11.06. | Iterum Therapeutics Inks Partnership With EVERSANA For Commercialization Of ORLYNVAH In US | 2 | RTTNews | ||
11.06. | Iterum Therapeutics plc - 8-K, Current Report | - | SEC Filings | ||
11.06. | Iterum Therapeutics PLC: Iterum Therapeutics Announces Partnership for Commercialization Services | 182 | GlobeNewswire (Europe) | U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
19.05. | Pfizer grants Iterum payment extension for FDA-approved antibiotic | 33 | Investing.com | ||
19.05. | Iterum Therapeutics PLC: Iterum Therapeutics Announces Extension of Term of Promissory Note | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 21,110 | +0,21 % | BioNTech SE: Pfizer and BioNTech's COMIRNATY Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 | The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1Shipping of the LP.8.1-adapted vaccine will... ► Artikel lesen | |
SANOFI | 84,97 | -0,83 % | Verhaltene Kauflaune bei Sanofi SA-Aktie (87,18 €) | Am Aktienmarkt ist der Anteilsschein von Sanofi SA zur Stunde unauffällig. Das Papier kostete zuletzt 87,18 Euro. Kaum verändert im Vergleich zu der letzten Notierung des vorigen Handelstages zeigt... ► Artikel lesen | |
ABBVIE | 178,00 | -0,11 % | AbbVie's RINVOQ Secures Health Canada's Approval For Giant Cell Arteritis Treatment | WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV), Wednesday announced Health Canada has issued a Notice of Compliance for RINVOQ for the treatment of adults with giant cell arteritis, both used in... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
INNOCAN PHARMA | 0,132 | +3,94 % | Die Ergebnisse von Innocan werden auf der Konferenz PAINWeek 2025 in Las Vegas, Nevada, im Rahmen eines wissenschaftlichen Posters präsentiert | - PAINWeek ist die wichtigste US-Konferenz im Bereich Schmerzmanagement
- Ein Highlight wird das Poster von Innocan "Is Long-Acting Synthetic Cannabidiol a Solution to Chronic... ► Artikel lesen | |
ABBOTT LABORATORIES | 113,58 | +0,98 % | The top Abbott stories of 2025 so far | ||
EDWARDS LIFESCIENCES | 69,19 | -0,56 % | Pulnovo Medical appoints Edwards Lifesciences veteran as CMO | ||
SCHOTT PHARMA | 22,900 | -0,43 % | Schott Pharma-Aktie leicht im Minus (23,05 €) | Am deutschen Aktienmarkt notiert die Aktie von Schott Pharma zur Stunde leichter. Die Aktie notiert aktuell bei 23,05 Euro. An der deutschen Börse hat sich heute die Aktie von Schott Pharma zwischenzeitlich... ► Artikel lesen | |
ASSEMBLY BIOSCIENCES | 21,400 | -1,83 % | Assembly Biosciences: Mega-Daten und Investoren-Ansturm | Es geht Schlag auf Schlag: Heute Morgen erst hatte ich über die neuesten, positiven Entwicklungen bei Assembly Biosciences berichtet, schon folgen die nächsten Kracher, die für ein neues Kurshoch sorgen.... ► Artikel lesen | |
PENTIXAPHARM | 1,754 | 0,00 % | Pentixapharm Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
NEKTAR THERAPEUTICS | 24,800 | -1,59 % | Nektar Therapeutics Reports Second Quarter 2025 Financial Results | SAN FRANCISCO, Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025.
Cash... ► Artikel lesen | |
CASSAVA SCIENCES | 2,018 | -1,13 % | Cassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business Update | Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyRecent appointment of experienced... ► Artikel lesen | |
CANTOURAGE GROUP | 3,900 | -1,27 % | Original-Research: Cantourage Group SE (von Montega AG): Kaufen | Original-Research: Cantourage Group SE - von Montega AG
15.07.2025 / 13:14 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
AXSOME THERAPEUTICS | 103,55 | -0,62 % | Axsome stock rating reiterated by H.C. Wainwright amid generic challenge | ||
ZEALAND PHARMA | 58,46 | -1,68 % | Zealand Pharma Announces Financial Results for the First Half of 2025 | Company announcement - No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments... ► Artikel lesen |